2-(5-chloro-1-methyl-1H-indol-3-yl)ethanamine | 682802-84-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(5-chloro-1-methyl-1H-indol-3-yl)ethanamine
• 英文别名: 2-(5-chloro-1-methyl-indol-3-yl)-ethylamine；2-(5-Chlor-1-methyl-indol-3-yl)-aethylamin；5-chloro-1-methyl-1H-indole-3-ethanamine；2-(5-Chloro-1-methyl-1H-indol-3-yl)-ethylamine；2-(5-chloro-1-methylindol-3-yl)ethanamine
• CAS: 682802-84-2
• 化学式: C₁₁H₁₃ClN₂
• mdl: MFCD02683923
• 分子量: 208.691
• InChiKey: UUCUKWNPBAJYFA-UHFFFAOYSA-N

物化性质

• 沸点：
  363.1±27.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  31
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(5-chloro-1-methyl-1H-indol-3-yl)ethanamine 在 potassium phosphate 、 1,10-菲罗啉 、 copper(ll) sulfate pentahydrate 、 silver trifluoromethanesulfonate 、 N-氟代双苯磺酰胺 、 三乙胺 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 12.08h， 生成 10-chloro-7-methyl-2,6-diphenyl-15-tosyl-5,7-dihydro-1H-5,11b-(epiminoethano)[1,2,4]triazolo[1’,2’:1,2]pyridazino[4,3-b]indole-1,3(2H)-dione
  参考文献：
  名称：

  氮杂[4,5-b]吲哚对烃咔唑衍生物和相关杂环的Diels-Alder环加成

  摘要：

  通过 Brønsted 酸引发的 Diels-Alder 环加成/retro-aza-Michael 加成级联过程，从 azepino[4,5- b ] 吲哚和市售的双烯体中开发了一种在 C4a 位置具有全碳四元中心的烃咔唑的方法。该方法以 63-99% 的收率提供了一系列烃类。这种转化的实用性通过放大实验和对几种烃类衍生物和四环二氢吲哚支架的各种转化得到证明。此外，用 4-phenyl-3 H -1,2,4-triazole-3,5(4 H )-dione (PTAD) 和 82探索了 azepino[4,5- b ] 吲哚的杂 Diels-Alder 环加成反应。获得了 –99% 的收率。

  DOI：

  10.1002/adsc.202101401
• 作为产物：
  描述：

  piperidine-2,3-dione-3-(4-chloro-phenylhydrazone) 在 盐酸 、 氢氧化钾 、 甲酸 、 溶剂黄146 、 丙酮 作用下， 生成 2-(5-chloro-1-methyl-1H-indol-3-yl)ethanamine
  参考文献：
  名称：

  881.色胺，咔啉和相关化合物。第三部分 1-甲基-和1：N-二甲基-色胺

  摘要：

  DOI：

  10.1039/jr9560004593

文献信息

• [EN] INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] DÉRIVÉS D'INDOLAMIDE ET COMPOSÉS ASSOCIÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DES MALADIES NEURODÉGÉNÉRATIVES
  申请人：UNIV LEUVEN KATH

  公开号：WO2010142801A1

  公开（公告）日：2010-12-16

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  本发明提供了新型化合物，以及这些新型化合物作为药物的使用，特别是用于预防或治疗神经退行性疾病，更具体地是一些神经系统疾病，例如统称为tauopathies的疾病，以及以细胞毒性α-突触核蛋白淀粉样蛋白生成为特征的疾病。本发明还涉及将所述新型化合物用于制造用于治疗此类神经退行性疾病的药物。本发明还涉及包括所述新型化合物的药物组合物，以及制备所述新型化合物的方法。
• NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Griffioen Gerard

  公开号：US20130274260A1

  公开（公告）日：2013-10-17

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1) wherein R 1 , R 2 , R 4 , R 6 , E, n, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , L, B, R 8 , and m are as defined in the claims.

  本发明提供了新型化合物，以及这些新型化合物作为药物的使用，特别是用于预防或治疗神经退行性疾病，更具体地是一些神经系统疾病，例如统称为tauopathies的疾病，以及以细胞毒性α-突触核蛋白淀粉样生成特征的疾病。本发明还涉及使用这些新型化合物来制造用于治疗此类神经退行性疾病的药物。本发明还涉及包括这些新型化合物的药物组合物以及制备这些新型化合物的方法。这些化合物的公式为(A1)，其中R1、R2、R4、R6、E、n、Y1、Y2、Y3、Y4、Y5、L、B、R8和m如权利要求中所定义。
• [EN] SUBSTITUTED INDOLYL ALKYL AMINO DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] DERIVES D'INDOLYL ALKYL AMINE SUBSTITUES UTILISES EN TANT QUE NOUVEAUX INHIBITEURS D'HISTONE DEACETYLASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2006010750A1

  公开（公告）日：2006-02-02

  This invention comprises the novel compounds of formula (I) wherein R1 , R2, R3, X and Y have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.

  这项发明包括具有组分(I)的新化合物，其中R1、R2、R3、X和Y具有定义的含义，具有组蛋白去乙酰化酶抑制酶活性；它们的制备、含有它们的组合物以及它们作为药物的用途。
• SUBSTITUTED INDOLYL ALKYL AMINO DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE
  申请人：Janssen Pharmaceutica NV

  公开号：US20150342950A1

  公开（公告）日：2015-12-03

  This invention comprises the novel compounds of formula (I) wherein R 1 , R 2 , R 3 , X and Y have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.

  本发明涉及公式（I）中的新化合物，其中R1、R2、R3、X和Y具有定义的含义，具有组蛋白去乙酰化酶抑制酶活性；它们的制备，包含它们的组合物以及它们作为药物的用途。
• INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Griffioen Gerard

  公开号：US20120083475A1

  公开（公告）日：2012-04-05

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  该发明提供了新型化合物，以及这些新型化合物用作药物，特别是用于预防或治疗神经退行性疾病，更具体地说是某些神经系统疾病，例如被统称为tau病理学的疾病，以及由细胞毒性α-突触蛋白淀积所特征的疾病。本发明还涉及使用这些新型化合物制备治疗这种神经退行性疾病的药物。本发明还涉及包括这些新型化合物的制药组合物，以及制备这些新型化合物的方法。